Himension Capital Singapore PTE. LTD. Buys 14,383 Shares of Tempus AI, Inc. $TEM

Himension Capital Singapore PTE. LTD. increased its stake in Tempus AI, Inc. (NASDAQ:TEM) by 42.6% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 48,114 shares of the company’s stock after purchasing an additional 14,383 shares during the quarter. Himension Capital Singapore PTE. LTD.’s holdings in Tempus AI were worth $2,176,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TEM. JPL Wealth Management LLC purchased a new stake in Tempus AI during the 3rd quarter worth about $26,000. Los Angeles Capital Management LLC purchased a new position in Tempus AI during the 4th quarter valued at about $27,000. Harvest Fund Management Co. Ltd purchased a new position in Tempus AI during the 3rd quarter valued at about $38,000. Whittier Trust Co. increased its position in shares of Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after buying an additional 570 shares during the period. Finally, Lodestone Wealth Management LLC bought a new stake in shares of Tempus AI during the fourth quarter valued at about $42,000. 24.22% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, CFO James William Rogers sold 11,529 shares of Tempus AI stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the sale, the chief financial officer owned 114,866 shares of the company’s stock, valued at $6,317,630. The trade was a 9.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 33,284 shares of the company’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $57.39, for a total value of $1,910,168.76. Following the completion of the transaction, the chief executive officer owned 167,763 shares of the company’s stock, valued at $9,627,918.57. The trade was a 16.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 616,043 shares of company stock valued at $31,748,593. 24.26% of the stock is currently owned by company insiders.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $48.98 on Wednesday. The company’s fifty day moving average price is $51.64 and its 200-day moving average price is $53.84. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. The firm has a market capitalization of $8.80 billion, a price-to-earnings ratio of -28.48 and a beta of 3.46. Tempus AI, Inc. has a one year low of $41.73 and a one year high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. During the same period in the previous year, the firm posted ($0.24) EPS. The firm’s revenue was up 36.1% compared to the same quarter last year. On average, equities research analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: The Personalis acquisition could deepen Tempus AI’s position in precision oncology and expand its addressable market in cancer monitoring. Tempus AI (TEM) Is Buying Personalis For $1.5 Billion To Deepen Cancer Monitoring
• Positive Sentiment: Needham reaffirmed a Buy rating and set a $75 price target, suggesting analysts still see meaningful upside despite the transaction-related selloff. Needham on Tempus AI Inc (TEM): ‘Buyers of any weakness related to the transaction’
• Neutral Sentiment: Tempus said it signed a definitive merger agreement to acquire Personalis, giving investors more clarity on the structure and terms of the deal. Tempus AI Announces Merger Agreement to Acquire Personalis
• Negative Sentiment: The market is reacting cautiously to the size of the deal, likely due to dilution, integration risk, and the fact that both stocks fell after the announcement. Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

Analyst Upgrades and Downgrades

TEM has been the subject of a number of analyst reports. Guggenheim raised their price objective on shares of Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Wall Street Zen lowered shares of Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. TD Cowen reissued a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $75.00 price target on shares of Tempus AI in a research report on Monday. Nine research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $68.92.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.